Co-Diagnostics, Inc. to Conduct Product Training Seminars with Distributor and Customers in the Dominican Republic
November 26 2018 - 06:30AM
Business Wire
Trainings will be conducted for staff and
customers of Laboratorios Franja, followed by launch of Company’s
products in DR
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that
Company distributor in the Dominican Republic, Laboratorios Franja,
will be hosting training seminars for its customers and sales
trainings for its staff in advance of launching the Company’s
products throughout that country.
Co-Diagnostics recently selected Laboratorios Franja S.R.L. as
the exclusive distributor of its diagnostics and Research Use Only
(RUO) products throughout the Dominican Republic, a country of
nearly 12 million people. The Company expects the initial product
launch to include the CE-IVD Logix Smart™ tests for tuberculosis
and Zika, other RUO products according to customer demand, and
distribution of the CoDx Box™, a magnetic induction thermocycler
with software optimized to run the Company’s polymerase chain
reaction (PCR) products. Laboratorios Franja, an ISO 9001:2015
certified company, has also agreed to assist the Company with all
local registration requirements needed to allow import and sale of
its products in the Dominican Republic.
Mr. Cameron Gundry, Co-Diagnostics Director of Commercialization
for Latin America, commented, “We are pleased with the progress
made so far by Laboratorios Franja in generating interest for our
products in the Dominican Republic, and completing the necessary
registration steps for our products and company. We look forward to
the valuable opportunities that this relationship creates for both
parties, as well as the economic benefits of participating in the
development and expansion of PCR technology across the Dominican
Republic market.
Our official product launch into the Dominican Republic is a
significant step for the commercialization of our company’s
products, and one that shows our ability to build on the momentum
we have been creating over the past several months. Our dedicated
sales team continues to add to our distributor network worldwide in
anticipation of following the same model in other countries that is
now being implemented in the Dominican Republic, and those markets
will be notified as similar training seminars and product
demonstrations are scheduled.”
The training seminars will showcase demonstrations of the
Company’s PCR products. They will be conducted by Company
representatives and are scheduled to occur on November 27-28 at
Laboratorios Franja’s headquarters in Santo Domingo, Dominican
Republic with up to 20 laboratories and hospitals. Attendance is by
invitation only. To request an invitation, contact the Company
using the information at the bottom of this release, or
Laboratorios Franja at info@laboratoriosfranja.com.
About Laboratorios Franja S.R.L.:
Laboratorios Franja is one of the most complete and efficient
microbiology laboratories in Santo Domingo, offering distribution
and sales of microbiology chemistry (cosmetics, medical equipment
and cleaning) products, and food quality/safety, environmental
microbiology and physical water chemistry
analyses. Laboratorios Franja also markets and distributes
high quality culture media, and related state-of-the-art
technology. Owned and operated by Frank Reyes, the distributor
has a highly qualified team of medical, lab staff and sales staff,
and can be found online at www.laboratoriosfranja.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company with a proprietary diagnostic testing
technology and development platform that intends to manufacture and
sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and license the use of its platform to other non-competing
developers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181126005156/en/
Company Contact:Denny CrockettCo-Diagnostics Sales
Representative801-438-1036d.crockett@codiagnostics.com
Investor Contact:Joe Diaz, Robert Blum and Joe
DorameLytham Partners, LLC602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2023 to Mar 2024